Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

103.39USD
1 Oct 2014
Price Change (% chg)

$1.24 (+1.21%)
Prev Close
$102.15
Open
$102.31
Day's High
$103.64
Day's Low
$101.86
Volume
162,293
Avg. Vol
192,591
52-wk High
$104.66
52-wk Low
$60.64

EW.N

Chart for EW.N

About

Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or... (more)

Overall

Beta: 0.55
Market Cap (Mil.): $10,831.31
Shares Outstanding (Mil.): 106.03
Dividend: --
Yield (%): --

Financials

Search Stocks

UPDATE 2-Legal settlement lifts Edwards Lifesciences' profit

July 29 - Edwards Lifesciences Corp posted stronger second-quarter earnings on Tuesday, propelled by a gain from a legal settlement and higher sales of heart valves that are implanted using a less-invasive procedure than traditional open-heart surgery.

30 Jul 2014

Edwards Lifesciences posts higher profit

July 29 - Edwards Lifesciences Corp posted stronger second-quarter earnings on Tuesday, propelled by a gain from a legal settlement and higher sales of its heart valves that are implanted in a less-invasive procedure than traditional open-heart surgery.

30 Jul 2014

Edwards wins U.S. nod for next generation Sapien XT heart valve system

- Edwards Lifesciences Corp said on Monday that U.S. health regulators approved its next generation heart valve replacement system for high risk patients and those deemed too frail to endure open heart surgery.

17 Jun 2014

Edwards wins U.S. nod for next generation Sapien XT heart valve system

June 16 - Edwards Lifesciences Corp said on Monday that U.S. health regulators approved its next generation heart valve replacement system for high risk patients and those deemed too frail to endure open heart surgery.

17 Jun 2014

Medtronic settles heart valve patent fight with rival Edwards

- Medtronic Inc agreed to pay more than $1 billion to rival Edwards Lifesciences Corp to settle patent litigation and keep its CoreValve artificial heart valve on the U.S. market.

20 May 2014

UPDATE 3-Medtronic settles heart valve patent fight with rival Edwards

May 20 - Medtronic Inc agreed to pay more than $1 billion to rival Edwards Lifesciences Corp to settle patent litigation and keep its CoreValve artificial heart valve on the U.S. market.

20 May 2014

Medtronic settles heart valve patent dispute with Edwards

May 20 - Medtronic Inc on Tuesday said it has agreed to pay royalties to rival medical device maker Edwards Lifesciences Corp in a settlement agreement that allows Medtronic to continue to sell its CoreValve replacement heart valves.

20 May 2014

Edwards Lifesciences 1st-qtr net profit falls, sales rise 5 pct

April 24 - Medical device maker Edwards Lifesciences Corp said on Thursday quarterly net earnings fell due to higher manufacturing costs, unfavorable foreign exchange rates and a year-earlier gain of $83.6 million related to patent litigation.

25 Apr 2014

U.S. court postpones injunction against Medtronic heart valve

- A U.S. appeals court on Monday postponed an injunction that would have stopped Medtronic Inc from selling its CoreValve heart valve implant in competition with Edwards Lifesciences Corp's Sapien valve product.

22 Apr 2014

U.S. court postpones injunction against Medtronic heart valve

April 21 - A U.S. appeals court on Monday postponed an injunction that would have stopped Medtronic Inc from selling its CoreValve heart valve implant in competition with Edwards Lifesciences Corp's Sapien valve product.

22 Apr 2014

Competitors

Earnings vs. Estimates

Search Stocks